Leonard N Boggs
Overview
Explore the profile of Leonard N Boggs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hyslop P, Boggs L, Chaney M
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982600
HO-oxidized glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalytic cysteine residues (C(SH) undergo rapid S-glutathionylation. Restoration of the enzyme activity is accomplished by thiol/disulfide S2 displacement (directly or enzymatically) forming glutathione disulfide (G(SS)G) and...
2.
Willis B, Lowe S, Monk S, Cocke P, Aluise C, Boggs L, et al.
J Alzheimers Dis Rep
. 2022 Mar;
6(1):1-15.
PMID: 35243208
Background: The development of beta-site amyloid-beta precursor protein cleaving enzyme (BACE) 1 inhibitors for the treatment of Alzheimer's disease requires optimization of inhibitor potency, selectivity, and brain penetration. Moreover, there...
3.
McKinzie D, Winneroski L, Green S, Hembre E, Erickson J, Willis B, et al.
J Med Chem
. 2021 Jun;
64(12):8076-8100.
PMID: 34081466
The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer's disease drug target owing to its critical role in the production of amyloid-beta. We have...
4.
Winneroski L, Erickson J, Green S, Lopez J, Stout S, Porter W, et al.
Bioorg Med Chem
. 2019 Dec;
28(1):115194.
PMID: 31786008
Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease. We previously reported the fragment-based discovery of LY2811376,...
5.
Winneroski L, Schiffler M, Erickson J, May P, Monk S, Timm D, et al.
Bioorg Med Chem
. 2015 May;
23(13):3260-8.
PMID: 26001341
The BACE1 enzyme is a key target for Alzheimer's disease. During our BACE1 research efforts, fragment screening revealed that bicyclic thiazine 3 had low millimolar activity against BACE1. Analysis of...
6.
May P, Willis B, Lowe S, Dean R, Monk S, Cocke P, et al.
J Neurosci
. 2015 Jan;
35(3):1199-210.
PMID: 25609634
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of...
7.
May P, Dean R, Lowe S, Martenyi F, Sheehan S, Boggs L, et al.
J Neurosci
. 2011 Nov;
31(46):16507-16.
PMID: 22090477
According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is critical for Alzheimer's disease (AD) pathogenesis. Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor...
8.
Yang H, Chai X, Mosior M, Kohn W, Boggs L, Erickson J, et al.
J Neurochem
. 2004 Dec;
91(6):1249-59.
PMID: 15584902
Beta-amyloid peptides (Abeta) are produced by a sequential cleavage of amyloid precursor protein (APP) by beta- and gamma-secretases. The lack of Abeta production in beta-APP cleaving enzyme (BACE1)(-/-) mice suggests...